Literature DB >> 26850597

Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys.

Myong Ki Baeg1, Seung Kew Yoon2, Sun-Hye Ko1, Kyung-Do Han3, Hye Jin Choi1, Si Hyun Bae1, Jong Young Choi1, Myung-Gyu Choi1.   

Abstract

BACKGROUND: Hepatic osteodystrophy has been reported in patients with various chronic liver diseases, including liver cirrhosis. However, it has not been well investigated in patients with hepatitis B virus infection. The aim of this study was to investigate the association between hepatitis B surface antigen (HBsAg) seropositivity and bone mineral density (BMD) in a population representative of normal Koreans.
METHODS: Subjects with both HBsAg and BMD levels examined during the 2008-2010 Korea National Health and Nutrition Examination Surveys were included. HBsAg-seropositive (+) subjects were compared with those who were HBsAg-seronegative (-). BMD was measured at the lumbar spine and femur by dual-energy X-ray absorptiometry. Multivariable logistic regression was performed for BMD .
RESULTS: In total, 11,306 participants were included in this study, among which 423 (3.7 %) were HBsAg(+): 153 premenopausal female (3.4 %), 83 postmenopausal female (3.5 %), and 187 male (4.2 %). Multivariable logistic regression analysis adjusted for age and body mass index showed that HBsAg(+) male had significantly lower BMD of the femoral neck than HBsAg(-) male (0.810 ± 0.009 vs. 0.827 ± 0.002 g/cm(2), p = 0.035). Further adjustment for waist circumference, smoking, drinking, exercise, income, occupation, and vitamin D levels showed that HBsAg(+) male had significantly lower BMD of the femur neck (0.810 ± 0.010 vs. 0.831 ± 0.002 g/cm(2), p = 0.032) and lumbar spine (0.953 ± 0.011 vs. 0.974 ± 0.003 g/cm(2), p = 0.049) than HBsAg(-) male.
CONCLUSIONS: HBsAg seropositivity was significantly associated with lower BMD in male. Future long-term prospective studies investigating bone turnover markers and hormones are needed to better understand the pathophysiology and clinical significance of chronic hepatitis B virus-related hepatic osteodystrophy.

Entities:  

Keywords:  Bone mineral density; Hepatic osteodystrophy; Hepatitis B virus; Osteoporosis; Viral hepatitis

Mesh:

Substances:

Year:  2016        PMID: 26850597     DOI: 10.1007/s12072-015-9672-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  33 in total

1.  Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis.

Authors:  Jorge L Gonzalez-Calvin; Jose L Mundi; Francisco J Casado; Enrique G Olivares
Journal:  Gastroenterology       Date:  2004-04       Impact factor: 22.682

2.  Assessment of bone metabolism and mineral density in chronic viral hepatitis.

Authors:  Necati Yenice; Mübeccel Gümrah; Ozgür Mehtap; Ahmet Kozan; Sembol Türkmen
Journal:  Turk J Gastroenterol       Date:  2006-12       Impact factor: 1.852

3.  Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease.

Authors:  M P Duarte; M L Farias; H S Coelho; L M Mendonça; L M Stabnov; M do Carmo d Oliveira; R A Lamy; D S Oliveira
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

4.  Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.

Authors:  Yasuji Arase; Fumitaka Suzuki; Yoshiyuki Suzuki; Norio Akuta; Masahiro Kobayashi; Hitomi Sezaki; Tetsuya Hosaka; Yusuke Kawamura; Hiromi Yatsuji; Miharu Hirakawa; Kenji Ikeda; Shiun Dong Hsieh; Yuki Oomoto; Kazuhisa Amakawa; Hisahito Kato; Tamae Kazawa; Hiroshi Tsuji; Tetsuro Kobayashi; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2010-03       Impact factor: 2.327

5.  Hepatitis B: the virus and disease.

Authors:  T Jake Liang
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 6.  Bone disorders in chronic liver disease.

Authors:  Jane Collier
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

7.  Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis.

Authors:  Jorge L González-Calvin; Jose L Mundi; Francisco J Casado-Caballero; Ana C Abadia; Jose J Martin-Ibañez
Journal:  J Clin Endocrinol Metab       Date:  2009-11-06       Impact factor: 5.958

8.  Bone mineral density measurements, bone markers and serum vitamin D concentrations in men with chronic non-cirrhotic untreated hepatitis C.

Authors:  Luciana G S Orsini; Marcelo M Pinheiro; Charlles H M Castro; Antônio E B Silva; Vera L Szejnfeld
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

9.  Prevalence of dietary supplement use in Korean children and adolescents: insights from Korea National Health and Nutrition Examination Survey 2007-2009.

Authors:  Ji Ye Yoon; Hyun Ah Park; Jae Heon Kang; Kyung Woo Kim; Yang Im Hur; Jin Joo Park; Ran Lee; Hyun Hye Lee
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

10.  Sociodemographic disparities in the composition of metabolic syndrome components among adults in South Korea.

Authors:  Hyunjung Lim; Tuan Nguyen; Ryowon Choue; Youfa Wang
Journal:  Diabetes Care       Date:  2012-07-26       Impact factor: 19.112

View more
  3 in total

Review 1.  Bone health in HIV and hepatitis B or C infections.

Authors:  Emmanuel Biver; Alexandra Calmy; René Rizzoli
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-07       Impact factor: 5.346

2.  Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide.

Authors:  Takuma Okamura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Satoshi Miuma; Yasuhide Motoyoshi; Mio Yamashima; Shinobu Yamamichi; Makiko Koike; Yusuke Nakano; Tetsurou Honda; Hiroyuki Yajima; Osamu Miyazaki; Yasutaka Kuribayashi; Tomonari Ikeda; Naota Taura; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2021-11-24

3.  Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate.

Authors:  Chunmei Li; Hui Li; Ming Gong; Jia Wei
Journal:  Clin Case Rep       Date:  2022-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.